Navigation Links
New non-surgical treatment for common, vexing eye condition
Date:3/31/2014

Baltimore, MD, 31 March 2014. A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.

The newly published report shows that eye drops containing the anti-anginal drug dipyridamole (Persantin, Cardoxin) led to almost total disappearance of an inflamed pterygium in a 35 year old otherwise healthy woman.

Dipyridamole is a drug in use over the past 55 years to treat other disorders, but now found to have this remarkable new use.

Pterygium is a disorder in which a non-cancerous growth develops on the white conjunctiva of the eye and over time invades the cornea. In some countries it affects up to 25% of the population. As the growth spreads, patients can develop vision problems as well as significant discomfort from complications such as dry eye, inflammation, irritation, and foreign body sensation. Additionally, because of their location in the eyes, pterygia are a cause of substantial cosmetic concern for sufferers.

Until now, eye surgery has been the only curative option, aided by medications trying to lessen the disorder's symptoms. However, even after eye surgery, pterygia often recur.

The new report's lead author, Moshe Rogosnitzky, who is Co-Founder and Director of Research at the MedInsight Research Institute, discovered that administration of dipyridamole eye drops significantly reduced a pterygium and completely resolved the associated inflammation and other symptoms.

Clinical trials are now being plannedfor pterygia, pingueculae, and other common eye disorders and their complications such as dry eye and inflammation.

One particular advantage to this discovery is that dipyridamole is a widely-approved anti-thrombosis medication that has been in use for over 55 years. Its safety profile is well-established; as such, fast-track development of dipyridamole eye drops as a repurposed drug is feasible.

Moshe Rogosnitzky commented on this finding, "Pterygium and dry eye are debilitating disorders for which new safe solutions are urgently needed, and I believe dipyridamole has the potential to provide relief to sufferers of these intractable conditions.

Rogosnitzky, who specializes in finding new uses for old drugs, continued, "This is yet another example of the advantages of drug repurposing. Whereas bringing a new drug to market can take up to 17 years or more, finding a new use for an old drug with an excellent safety profile can lead to approval and availability in as little as two years."


'/>"/>
Contact: Deena Illions
deena1@medinsight.org
443-927-7755
MedInsight Research Institute
Source:Eurekalert  

Related medicine news :

1. Masha Banar, Board Certified Physician Associate, Now Offers Non-Surgical Rhinoplasty for Correction of Complications After Surgical Rhinoplasty
2. Cosmetic Laser Institute in Orange County Introduces Non-Surgical Fat Reduction with Exilis
3. Barnes-Jewish Hospital Offering New FDA-approved Non-surgical Procedure for Mitral Valve Repair
4. Lipo Body Sculpture of Houston Announces Breakthrough Treatment for Non-Surgical Neck Tightening
5. Masha Banar, PA-C of Visage Sculpture, Non-surgical Face Shaping Cosmetic Practice of Boston, Confirms Resistance Forming to Botox over Time, Less to Dysport.
6. Non-surgical Facelift, Specialty of Masha Banar PA-C of Visage Sculpture, Got a "Lift": Retrospective Comparison of Radiesse, Sculptra, and Perlane
7. Horwitz Dermatology Now Offers Non-Surgical Ultrasound Skin Tightening Treatments
8. Brandith Irwin, MD, of SkinTour.com Answers New Blog Question About Improving Neck Skin Non-Surgically
9. Visage Sculpture, Non-Surgical Face Shaping Cosmetic Practice of Boston, Announces Using Microcannulas to Make Non-Surgical Rhinoplasty Safer
10. Living Well Medical Introduces Groundbreaking Non-Surgical Therapies for Osteoarthritis Knee Pain
11. Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New non-surgical treatment for common, vexing eye condition
(Date:2/9/2016)... ... February 09, 2016 , ... Center for Autism ... diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering ... analysis (ABA) is key to providing effective treatment for individuals with ASD. Now, ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global breast ... Hung to the company´s Board of Directors. , “We are honored to ... an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge ...
(Date:2/9/2016)... ... ... Dr. Rassouli, cosmetic dentist in Orange County , is now offering ... procedures in dentistry today, but the cost often leads to patients looking to less ... whitening-related damage. For a limited time, Dr. Rassouli is offering this special whitening package ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... , Feb.8, 2016 Cardiovascular Surgery ... Summary GlobalData,s Medical Devices sector report, "Cardiovascular ... provides an overview of Cardiovascular Surgery Devices currently ... --> The report provides comprehensive information ... the products at various stages of development. The ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , ... and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they ... development and commercialization rights for OPA-15406 in the U.S. ... also provides manufacturing rights.  OPA-15406 is a topical, non-steroidal ... atopic dermatitis. --> --> ...
Breaking Medicine Technology: